See more : Devro plc (DVO.L) Income Statement Analysis – Financial Results
Complete financial analysis of Purple Biotech Ltd. (PPBT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Purple Biotech Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Global Technology Acquisition Corp. I (GTAC) Income Statement Analysis – Financial Results
- Westpac Banking Corporation (WBK) Income Statement Analysis – Financial Results
- Pacifico Acquisition Corp. (PAFOR) Income Statement Analysis – Financial Results
- Barrick Gold Corporation (GOLD) Income Statement Analysis – Financial Results
- TransCode Therapeutics, Inc. (RNAZ) Income Statement Analysis – Financial Results
Purple Biotech Ltd. (PPBT)
About Purple Biotech Ltd.
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | -910.00K | -320.00K | 1.00M | 1.00M | 1.00M | 901.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 196.00K | 201.00K | 231.00K | 235.00K | 80.00 | 0.00 | 4.00K | 2.00K | 999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -196.00K | -1.11M | -551.00K | 765.00K | 999.92K | 1.00M | 897.00K | -2.00K | -999.76 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 122.09% | 172.19% | 76.50% | 99.99% | 100.00% | 99.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.03M | 16.32M | 11.83M | 7.49M | 2.67M | 5.27M | 4.64M | 4.18M | 2.56M | 3.19M | 109.00K | 94.00 |
| General & Administrative | 0.00 | 5.96M | 5.82M | 6.07M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Selling & Marketing | 0.00 | 321.00K | 286.00K | 235.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.04M | 6.28M | 6.11M | 6.31M | 6.08M | 4.45M | 6.39M | 3.00M | 1.51M | 1.27M | 1.06M | 608.00 |
| Other Expenses | -44.54M | 0.00 | 0.00 | -15.66M | -216.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -22.47M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Cost & Expenses | -22.27M | 22.60M | 17.93M | 13.79M | 8.75M | 8.83M | 12.06M | 7.18M | 4.07M | 5.18M | 1.17M | 703.00 |
| Interest Income | 474.00K | 969.00K | 320.00K | 254.00K | 151.00K | 93.00K | 106.00K | 138.00K | 94.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 2.18M | 126.00K | 212.00K | 61.00K | 181.00K | 576.00K | 26.00K | 6.00K | 3.00K | 21.00K | 48.00K | 0.00 |
| Depreciation & Amortization | 199.00K | 201.00K | 231.00K | 235.00K | 178.00K | 7.00K | 4.00K | 2.00K | 1.00K | -50.00K | -27.00K | 957.22 |
| EBITDA | -22.23M | -21.49M | -17.52M | -28.41M | -6.14M | -5.55M | -12.88M | -7.04M | -4.20M | -5.43M | -2.58M | 255.22 |
| EBITDA Ratio | 0.00% | 2,355.27% | 5,432.19% | -2,796.00% | -763.80% | -772.60% | -1,323.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | 22.27M | -22.60M | -17.93M | 12.61M | -7.16M | -7.83M | -12.25M | -7.18M | -4.07M | -5.18M | -2.55M | -702.00 |
| Operating Income Ratio | 0.00% | 2,483.85% | 5,604.38% | 1,261.20% | -715.60% | -782.60% | -1,359.16% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -42.25M | -43.52M | 108.00K | -15.46M | 1.48M | 2.26M | -947.00K | -4.94M | -133.00K | -71.00K | -75.00K | -1.00 |
| Income Before Tax | -19.98M | -21.76M | -17.83M | -28.07M | -5.89M | -5.57M | -13.01M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Income Before Tax Ratio | 0.00% | 2,391.21% | 5,570.63% | -2,807.40% | -589.30% | -556.90% | -1,443.73% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -935.00K | 637.00K | -15.67M | 216.00K | -2.63M | 26.00K | 4.94M | 133.00K | 50.00K | 27.00K | 0.00 |
| Net Income | -19.88M | -20.83M | -18.46M | -12.41M | -6.11M | -5.20M | -12.27M | -12.13M | -4.20M | -5.25M | -2.63M | -703.00 |
| Net Income Ratio | 0.00% | 2,288.46% | 5,769.69% | -1,240.50% | -610.90% | -520.00% | -1,362.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.49 |
| EPS Diluted | -0.09 | -1.13 | -1.04 | -0.72 | -3.15 | -0.27 | -0.63 | -0.62 | -0.22 | -234.38 | -320.25 | -10.41 |
| Weighted Avg Shares Out | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.00 |
| Weighted Avg Shares Out (Dil) | 221.33M | 18.48M | 17.80M | 17.21M | 1.94M | 19.54M | 19.54M | 19.54M | 19.54M | 22.41K | 8.21K | 67.55 |
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Contribution of NK cells engager arm and conditionally activated T cell engager demonstrated Cleavable capping technology confines therapeutic activity to the local tumor micro environment which increases the anticipated therapeutic window in patients REHOVOT, Israel, March 14, 2024 (GLOBE NEWSWIRE)...
Here's Why Purple Biotech Ltd. Sponsored ADR (PPBT) Could be Great Choice for a Bottom Fisher
Purple Biotech Ltd. Sponsored ADR (PPBT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately.
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
Purple Biotech (NASDAQ: PPBT ) just reported results for the fourth quarter of 2023. Purple Biotech reported earnings per share of -19 cents.
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
REHOVOT, Israel, March 05, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
NT219 was well tolerated Anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR) REHOVOT, Israel, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the...
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
NT219 recommended dose established, anti-tumor activity demonstrated REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd . ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor...
Purple Biotech Reaches Recommended Phase 2 Dose for NT219
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance,...
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
Dr. Margolin brings 35 years of expertise in biotechnology, pharma, and venture capital Purple Biotech also announces the resignation of Mr. Fabien Sebille, who served as the Company's Chief Business Officer REHOVOT, Israel, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Purple...
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
This acceleration of recruitment is expected to result in earlier look at overall survival of patients REHOVOT, Israel, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies...
Purple Biotech Reports Third Quarter 2023 Financial Results
Initial Activity in Head and Neck Cancer Demonstrated in NT219 Phase 1 /2 Do s e Escalation Study Patients ' E nrollment in the Phase 2 Randomized CM24 Pancreatic Cancer T rial A head of T imelines C ash R...
Source: https://incomestatements.info
Category: Stock Reports